



**ABBVIE SAVINGS PROGRAMS  
ELECTRONIC PAYMENT ENROLLMENT FORM**

The default payment method for the AbbVie savings programs is via mailed checks. To enable electronic funds transfer (EFT), also known as ACH, complete this form and fax it to 1-908-941-0463. After submitting the form, you will:

- Receive an email for your office to enter banking information. The email will come from either [ozurdexsavingsprogram@allerganeyecue.com](mailto:ozurdexsavingsprogram@allerganeyecue.com) or [durystasavingsprogram@allerganeyecue.com](mailto:durystasavingsprogram@allerganeyecue.com), depending on the product selected
- Receive a confirmation call from *Allergan EyeCue*® (if needed)

If your patient qualifies, you have submitted all the required documents for the AbbVie savings program, and they are approved, the estimated time for reimbursement is 3 days via EFT.

AbbVie product: (choose one)      (bimatoprost intracameral implant) 10 mcg      (dexamethasone intravitreal implant) 0.7 mg    *All fields and signature are required.*

- If you use both OZURDEX® and DURYSTA® in your practice, you must complete a separate enrollment form for each product
- If you have more than one practice NPI, you must submit an enrollment form for each one

<b>PRACTICE INFORMATION</b>	<p>As you complete the following section, please refer to the practice name, address, and NPI that will be included on the CMS-1500 form and enter the information for each item requested below.</p> <p><b>Practice name:</b> _____</p> <p><b>Practice address:</b> _____                  _____                  _____</p> <p><b>Practice NPI:</b> _____</p>
<b>PRACTICE CONTACT INFORMATION</b>	<p><b>Practice Contact Person</b></p> <p>This is the contact person who will be setting up the EFT, which entails receiving an email with a link to a secure site to submit bank information to finish enrollment. Please have bank routing and account information ready.</p> <p><b>Name:</b> _____</p> <p><b>Title:</b> _____</p> <p><b>Email</b> (where you'll receive the link to finish EFT enrollment): _____</p> <p><b>Phone number:</b> _____</p> <p><b>X</b> _____</p> <p><b>Contact person's signature</b> _____ <b>Date</b> _____</p>

**Privacy Notice:** For information on how we collect and process your personal data, including the categories we collect, purposes for their collection, and disclosures to third parties, visit <https://abbv.ie/PrivacyHCP>.

**Complete and fax to 1-908-941-0463.**  
**Questions? Contact 1-866-OZURDEX (1-866-698-7339) or 1-833-DURYSTA (1-833-387-9782), option 2.**

Please see Important Safety Information on the following pages.  
 Please see accompanying full [Prescribing Information](https://www.rxabbvie.com/pdf/durysta_pi.pdf) or visit [https://www.rxabbvie.com/pdf/durysta\\_pi.pdf](https://www.rxabbvie.com/pdf/durysta_pi.pdf)  
 Please see accompanying full [Prescribing Information](https://www.rxabbvie.com/pdf/ozurdex_pi.pdf) or visit [https://www.rxabbvie.com/pdf/ozurdex\\_pi.pdf](https://www.rxabbvie.com/pdf/ozurdex_pi.pdf)

## **DURYSTA® (bimatoprost intracameral implant) INDICATIONS, USAGE, AND IMPORTANT SAFETY INFORMATION**

### **Indications and Usage**

DURYSTA® (bimatoprost intracameral implant) is indicated for the reduction of intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension (OHT).

### **Important Safety Information**

#### **Contraindications**

DURYSTA® is contraindicated in patients with: active or suspected ocular or periocular infections; corneal endothelial cell dystrophy (e.g., Fuchs' Dystrophy); prior corneal transplantation or endothelial cell transplants (e.g., Descemet's Stripping Automated Endothelial Keratoplasty [DSAEK]); absent or ruptured posterior lens capsule, due to the risk of implant migration into the posterior segment; hypersensitivity to bimatoprost or to any other components of the product.

#### **Warnings and Precautions**

The presence of DURYSTA® implants has been associated with corneal adverse reactions and increased risk of corneal endothelial cell loss. Administration of DURYSTA® should be limited to a single implant per eye without retreatment. Caution should be used when prescribing DURYSTA® in patients with limited corneal endothelial cell reserve.

DURYSTA® should be used with caution in patients with narrow iridocorneal angles (Shaffer grade < 3) or anatomical obstruction (e.g., scarring) that may prohibit settling in the inferior angle.

Macular edema, including cystoid macular edema, has been reported during treatment with ophthalmic bimatoprost, including DURYSTA® intracameral implant. DURYSTA® should be used with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema.

Prostaglandin analogs, including DURYSTA®, have been reported to cause intraocular inflammation. DURYSTA® should be used with caution in patients with active intraocular inflammation (e.g., uveitis) because the inflammation may be exacerbated.

Ophthalmic bimatoprost, including DURYSTA® intracameral implant, has been reported to cause changes to pigmented tissues, such as increased pigmentation of the iris. Pigmentation of the iris is likely to be permanent. Patients who receive treatment should be informed of the possibility of increased pigmentation. While treatment with DURYSTA® can be continued in patients who develop noticeably increased iris pigmentation, these patients should be examined regularly.

Intraocular surgical procedures and injections have been associated with endophthalmitis. Proper aseptic technique must always be used with administering DURYSTA®, and patients should be monitored following the administration.

#### **Adverse Reactions**

In controlled studies, the most common ocular adverse reaction reported by 27% of patients was conjunctival hyperemia. Other common adverse reactions reported in 5%-10% of patients were foreign body sensation, eye pain, photophobia, conjunctival hemorrhage, dry eye, eye irritation, intraocular pressure increased, corneal endothelial cell loss, vision blurred, iritis, and headache.

**Please see accompanying full Prescribing Information or visit [https://www.rxabbvie.com/pdf/durysta\\_pi.pdf](https://www.rxabbvie.com/pdf/durysta_pi.pdf)**

## OZURDEX® (dexamethasone intravitreal implant) INDICATIONS, USAGE, AND IMPORTANT SAFETY INFORMATION

### Indications and Usage

#### Diabetic Macular Edema

OZURDEX® (dexamethasone intravitreal implant) is a corticosteroid indicated for the treatment of diabetic macular edema.

#### Retinal Vein Occlusion

OZURDEX® is a corticosteroid indicated for the treatment of macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO).

#### Posterior Segment Uveitis

OZURDEX® is indicated for the treatment of noninfectious uveitis affecting the posterior segment of the eye.

#### Dosage and Administration

FOR OPHTHALMIC INTRAVITREAL INJECTION. The intravitreal injection procedure should be carried out under controlled aseptic conditions. Following the intravitreal injection, patients should be monitored for elevation in intraocular pressure and for endophthalmitis. Patients should be instructed to report any symptoms suggestive of endophthalmitis without delay.

### IMPORTANT SAFETY INFORMATION

#### Contraindications

**Ocular or Periocular Infections:** OZURDEX® (dexamethasone intravitreal implant) is contraindicated in patients with active or suspected ocular or periocular infections including most viral diseases of the cornea and conjunctiva, including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections, and fungal diseases.

**Glaucoma:** OZURDEX® is contraindicated in patients with glaucoma, who have cup to disc ratios of greater than 0.8.

**Torn or Ruptured Posterior Lens Capsule:** OZURDEX® is contraindicated in patients whose posterior lens capsule is torn or ruptured because of the risk of migration into the anterior chamber. Laser posterior capsulotomy in pseudophakic patients is not a contraindication for OZURDEX® use.

**Hypersensitivity:** OZURDEX® is contraindicated in patients with known hypersensitivity to any components of this product.

#### Warnings and Precautions

**Intravitreal Injection-related Effects:** Intravitreal injections, including those with OZURDEX®, have been associated with endophthalmitis, eye inflammation, increased intraocular pressure, and retinal detachments. Patients should be monitored regularly following the injection.

**Steroid-related Effects:** Use of corticosteroids including OZURDEX® may produce posterior subcapsular cataracts, increased intraocular pressure, glaucoma, and may enhance the establishment of secondary ocular infections due to bacteria, fungi, or viruses.

Corticosteroids are not recommended to be used in patients with a history of ocular herpes simplex because of the potential for reactivation of the viral infection.

### Adverse Reactions

#### Diabetic Macular Edema

Ocular adverse reactions reported by greater than or equal to 1% of patients in the two combined 3-year clinical trials following injection of OZURDEX® for diabetic macular edema include: cataract (68%), conjunctival hemorrhage (23%), visual acuity reduced (9%), conjunctivitis (6%), vitreous floaters (5%), conjunctival edema (5%), dry eye (5%), vitreous detachment (4%), vitreous opacities (3%), retinal aneurysm (3%), foreign body sensation (2%), corneal erosion (2%), keratitis (2%), anterior chamber inflammation (2%), retinal tear (2%), eyelid ptosis (2%). Non-ocular adverse reactions reported by greater than or equal to 5% of patients include: hypertension (13%) and bronchitis (5%).

**Increased Intraocular Pressure:** IOP elevation greater than or equal to 10 mm Hg from baseline at any visit was seen in 28% of OZURDEX® patients versus 4% of sham patients. 42% of the patients who received OZURDEX® were subsequently treated with IOP-lowering medications during the study versus 10% of sham patients.

The increase in mean IOP was seen with each treatment cycle, and the mean IOP generally returned to baseline between treatment cycles (at the end of the 6-month period).

**Cataracts and Cataract Surgery:** The incidence of cataract development in patients who had a phakic study eye was higher in the OZURDEX® group (68%) compared with Sham (21%). The median time of cataract being reported as an adverse event was approximately 15 months in the OZURDEX® group and 12 months in the Sham group. Among these patients, 61% of OZURDEX® subjects versus 8% of sham-controlled subjects underwent cataract surgery, generally between Month 18 and Month 39 (Median Month 21 for OZURDEX® group and 20 for Sham) of the studies.

#### Retinal Vein Occlusion and Posterior Segment Uveitis

Adverse reactions reported by greater than 2% of patients in the first 6 months following injection of OZURDEX® for retinal vein occlusion and posterior segment uveitis include: intraocular pressure increased (25%), conjunctival hemorrhage (22%), eye pain (8%), conjunctival hyperemia (7%), ocular hypertension (5%), cataract (5%), vitreous detachment (2%), and headache (4%).

Increased IOP with OZURDEX® peaked at approximately week 8. During the initial treatment period, 1% (3/421) of the patients who received OZURDEX® required surgical procedures for management of elevated IOP.

**Please see accompanying full Prescribing Information or visit [https://www.rxabbvie.com/pdf/ozurdex\\_pi.pdf](https://www.rxabbvie.com/pdf/ozurdex_pi.pdf)**